1
|
Levy A, Roux C, Mercier O, Issard J, Botticella A, Barlesi F, Le Péchoux C. [Radiotherapy for oligometastatic non-small cell lung cancer patients]. Cancer Radiother 2021; 25:517-522. [PMID: 34175225 DOI: 10.1016/j.canrad.2021.06.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2021] [Accepted: 06/05/2021] [Indexed: 10/21/2022]
Abstract
The oligometastatic disease concept suggests that patients with a limited number of metastases have a favorable prognosis. Radical local treatment of oligometastatic patients has then increased given developments in imaging (mainly positron emission tomography and brain magnetic resonance imaging) and access to effective and better tolerated treatments. Stereotactic radiotherapy has the advantage of being noninvasive, allowing a good rate of local control and a limited number of side effects. A better definition of oligometastatic disease, particularly for non-small cell lung cancer (NSCLC), has recently been published. For patients with NSCLC, two randomized phase II trials also suggested that the addition of a radical local treatment results in encouraging survival data, with a good safety profile. A single-arm phase II finally showed a benefit when combining a radical local treatment with an anti-PD1 immunotherapy. This review describes the definitions of oligometastatic disease, the main prospective findings including radiation therapy, and prospects for oligometastatic NSCLC patients.
Collapse
Affiliation(s)
- A Levy
- Gustave-Roussy, département d'oncologie radiothérapie, 94805 Villejuif, France; Centre international des cancers thoraciques (CICT), Gustave-Roussy, 94805 Villejuif, France; Université Paris-Saclay, Inserm U1030, radiothérapie moléculaire, 94805 Villejuif, France; Université Paris-Saclay, faculté de médecine, 94270 Le Kremlin-Bicêtre, France.
| | - C Roux
- Centre international des cancers thoraciques (CICT), Gustave-Roussy, 94805 Villejuif, France; Département de radiologie, Gustave-Roussy, 94805 Villejuif, France
| | - O Mercier
- Centre international des cancers thoraciques (CICT), Gustave-Roussy, 94805 Villejuif, France; Université Paris-Saclay, faculté de médecine, 94270 Le Kremlin-Bicêtre, France; Département de chirurgie thoracique et vasculaire et transplantation cardiopulmonaire, groupe hospitalier Paris Saint-Joseph-Marie-Lannelongue, 92350 Le Plessis-Robinson, France
| | - J Issard
- Centre international des cancers thoraciques (CICT), Gustave-Roussy, 94805 Villejuif, France; Département de chirurgie thoracique et vasculaire et transplantation cardiopulmonaire, groupe hospitalier Paris Saint-Joseph-Marie-Lannelongue, 92350 Le Plessis-Robinson, France
| | - A Botticella
- Gustave-Roussy, département d'oncologie radiothérapie, 94805 Villejuif, France; Centre international des cancers thoraciques (CICT), Gustave-Roussy, 94805 Villejuif, France
| | - F Barlesi
- Centre international des cancers thoraciques (CICT), Gustave-Roussy, 94805 Villejuif, France; Gustave-Roussy Cancer Campus, Villejuif, France; Aix-Marseille université, Inserm, CNRS, CRCM, Marseille, France
| | - C Le Péchoux
- Gustave-Roussy, département d'oncologie radiothérapie, 94805 Villejuif, France; Centre international des cancers thoraciques (CICT), Gustave-Roussy, 94805 Villejuif, France
| |
Collapse
|
2
|
Barret E, Sanchez-Salas R, Galiano M, Cathala N, Mombet A, Prapotnich D, Rozet F, Gangi A, Lang H, Cathelineau X. [Management of ablative therapies in prostate cancer]. Prog Urol 2017; 27:909-925. [PMID: 28918872 DOI: 10.1016/j.purol.2017.07.243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2017] [Accepted: 07/20/2017] [Indexed: 10/18/2022]
Abstract
OBJECTIVES To describe the specific modalities of ablative therapies management in prostate cancer. MATERIALS AND METHODS A review of the scientific literature was performed in Medline database (http://www.ncbi.nlm.nih.gov) and Embase (http://www.embase.com) using different associations of keywords. Publications obtained were selected based on methodology, language and relevance. After selection, 61 articles were analysed. RESULTS Development of innovations such as ablative therapies in prostate cancer induces specific modalities in their management, during pre-, per- and post-procedure. More than for classical and well-known treatments, the decision to propose an ablative therapy requires analysis and consensus of medical staff and patient's agreement. Patient's specificities and economical aspects must also be considered. Procedures and follow-up must be realized by referents actors. CONCLUSION Indication, procedure and follow-up of ablative therapies in prostate cancer require specific modalities. They must be respected in order to optimize the results and to obtain a precise and objective evaluation for defining future indications.
Collapse
Affiliation(s)
- E Barret
- Département d'urologie, institut Montsouris, 42, boulevard Jourdan, 75014 Paris, France; Université Paris Descartes, 75006 Paris, France
| | - R Sanchez-Salas
- Département d'urologie, institut Montsouris, 42, boulevard Jourdan, 75014 Paris, France; Université Paris Descartes, 75006 Paris, France
| | - M Galiano
- Département d'urologie, institut Montsouris, 42, boulevard Jourdan, 75014 Paris, France; Université Paris Descartes, 75006 Paris, France
| | - N Cathala
- Département d'urologie, institut Montsouris, 42, boulevard Jourdan, 75014 Paris, France; Université Paris Descartes, 75006 Paris, France
| | - A Mombet
- Département d'urologie, institut Montsouris, 42, boulevard Jourdan, 75014 Paris, France; Université Paris Descartes, 75006 Paris, France
| | - D Prapotnich
- Département d'urologie, institut Montsouris, 42, boulevard Jourdan, 75014 Paris, France; Université Paris Descartes, 75006 Paris, France
| | - F Rozet
- Département d'urologie, institut Montsouris, 42, boulevard Jourdan, 75014 Paris, France; Université Paris Descartes, 75006 Paris, France
| | - A Gangi
- Service de radiologie interventionnelle, CHU de Strasbourg, 67000 Strasbourg, France
| | - H Lang
- Service de chirurgie urologique, CHU de Strasbourg, 67000 Strasbourg, France
| | - X Cathelineau
- Département d'urologie, institut Montsouris, 42, boulevard Jourdan, 75014 Paris, France; Université Paris Descartes, 75006 Paris, France.
| |
Collapse
|